Home › NDC Lookup › Ingredients › Pyridostigmine Bromide › 62559-0470-01
Pyridostigmine Bromide 60 mg Tablet, 100-count — NDC 62559-0470-01 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Pyridostigmine Bromide 60 mg Tablet, 100-count — NDC 62559-470-01 (Billing 62559-0470-01)

by ANI Pharmaceuticals, Inc. · 100 TABLET in 1 BOTTLE (62559-470-01)

NDC 62559-470-01 (billing 62559-0470-01) is a package of 100 tablets of Pyridostigmine Bromide 60 mg Tablet from ANI Pharmaceuticals, Inc., marketed since Jan 2024 and currently FDA-listed; retail pharmacies pay about $0.2487 per tablet (NADAC). It is this product's only package size.

NDC 62559-0470-01
🏷️ FDA NDC (as labeled) 62559-470-01 billing pads the product segment with a zero
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 62559-470-01
Product NDC 62559-470
11-digit billing NDC 62559047001
NCPDP billing unit EA — each (per item)
RxCUI 903857
UNII KVI301NA53
UPC 0362559470018
Application # ANDA040512
SPL Set ID 0a114d99-e50b-49fe-9e0f-ccce279ffb4f
Established class (EPC) Cholinesterase Inhibitor
Mechanism of action Cholinesterase Inhibitors
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2024-01-16
Route ORAL
Dosage form TABLET
Substance PYRIDOSTIGMINE BROMIDE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 76000050100305
GCN Seq No 004764
GCN 18530
HICL code 001990
Ingredient (HICL) Pyridostigmine Bromide
HIC1 code J
Therapeutic class — broad (HIC1) Autonomic Nervous System
HIC2 code J1
Therapeutic class — intermediate (HIC2) Cholinergics
HIC3 code J1B
Therapeutic class — specific (HIC3) Cholinesterase Inhibitors
AHFS code 12:04.00.00
AHFS class Parasympathomimetic (Cholinergic Agents)
FDB label name PYRIDOSTIGMINE BR 60 MG TABLET
FDB brand name Pyridostigmine Bromide
Legend status F — Federal legend — prescription drug or device
Quick answers for NDC 62559-470-01
  • GSN (GCN sequence number): 004764
  • GCN: 18530
  • GPI-14 (Medi-Span): 76000050100305
  • HICL (First Databank): 001990
  • AHFS class code: 12:04.00.00
  • RxCUI (RxNorm): 903857
  • 11-digit billing NDC: 62559047001
Why two NDCs? The FDA registers this code as 62559-470-01 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 62559-0470-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Cholinesterase Inhibitor class.

Pharmacologic class Cholinesterase Inhibitor
Drug family (ATC) Anticholinesterases
How it works Cholinesterase Inhibitors
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name PYRIDOSTIGMINE BR 60 MG TABLET Ingredient Pyridostigmine Bromide
📖 What it is MedlinePlus · NLM

Pyridostigmine is used to treat myasthenia gravis. Pyridostigmine is in a class called cholinergic agents. It works by increasing the amount of certain natural substances in the body to improve nerve and muscle activity.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It depends on the product. Mestinon and the oral solution treat myasthenia gravis. Regonol is a hospital injection that reverses muscle relaxants. Other tablets are for military us...
  • Take it exactly as prescribed. Oral products are swallowed, and doses are adjusted to your needs and spaced through the day. The military extended-release tablet must be taken with...
  • Stomach upset is most common, including diarrhea, cramps and nausea. Some people notice twitching, sweating or drooling. These come from extra acetylcholine activity, so tell your...
  • Get help right away for trouble breathing, severe dizziness, fainting, or growing muscle weakness. These can be signs of a serious reaction or too much medicine.
📖 Read our full Pyridostigmine guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.249 $24.87 / 100 tablets
Medicaid paysCMS SDUD · 12 mo $0.3322 $33.22 / 100 tablets
Medicare drug plans payPart D · Q2 2026 $0.3682 $36.82 / 100 tablets
NADAC price history (per ea) — tap or hover for the price & month
Dec 2025 Mar 2026 Jun 2026 Sep 2026 $0.273 $0.249
▼ Down 9% over the last 10 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
62559-0470-01 62559-470-01 You're viewing this Main listing 100 TABLET in 1 BOTTLE (62559-470-01) 2024-01-16 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Pyridostigmine Bromide 60 mg 68682-0302-10 Oceanside 100 tablets $0.197 AB Discontinued save 21%
Pyridostigmine Bromide 60 mg 00115-3511-01 Amneal 100 tablets $0.249 AB Availability likely —
pyridostigmine bromide 60 mg 00904-6622-61 Major 100 tablets $0.249 AB Availability likely —
Pyridostigmine Bromide 60 mgthis 62559-0470-01 ANI 100 tablets $0.249 AB Availability likely —
Pyridostigmine Bromide 60 mg 68084-0494-01 American 100 tablets $0.249 AB Availability likely —
Mestinon 60 mg 00187-3010-30 Bausch 100 tablets — AB FDA listed —
pyridostigmine bromide 60 mg 51407-0590-30 Golden 30 tablets — AB FDA listed —
Pyridostigmine Bromide 60 mg 58657-0811-01 Method 100 tablets — AB FDA listed —
pyridostigmine bromide 60 mg 65841-0819-01 Zydus 100 tablets — AB FDA listed —
pyridostigmine bromide 60 mg 68382-0659-01 Zydus 100 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2024
On the market since
Jan 2024
📍
2026
Currently FDA-listed
2 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color White
ShapeRound
ImprintANI;470
Size11 mm
ScoringScored — splits in 4
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 3SY5LH9PMK
    Anhydrous lactose is a milk sugar with no water content. It acts as a filler and binder in tablets and capsules, adding bulk and helping ingredients stick together.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
  • UNII 4ELV7Z65AP
    Stearic acid is a fatty acid derived from plant or animal sources. It acts as a binder and lubricant in tablets and capsules, helping them hold together and flow smoothly during manufacturing.

3 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerANI Pharmaceuticals, Inc.
Application holderANI PHARMACEUTICALS INC
FDA applicationANDA040512 (ANDA)
Labeler code62559
First marketedJan 2024
Product typeHuman Prescription Drug
Portfolio299 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description ⚠️ Precautions 📚 References 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 15 words ▾

INDICATIONS AND USAGE Pyridostigmine Bromide Tablets USP are useful in the treatment of myasthenia gravis.

⏱️ Dosage and Administration 100 words ▾

DOSAGE AND ADMINISTRATION Each Pyridostigmine Bromide Tablet contains 60 mg pyridostigmine bromide. Dosage The size and frequency of the dosage must be adjusted to the needs of the individual patient. The average dose is ten 60 mg tablets daily, spaced to provide maximum relief when maximum strength is needed.

In severe cases as many as twenty-five tablets a day may be required, while in mild cases one to six tablets a day may suffice. NOTE: For information on a diagnostic test for myasthenia gravis, and for the evaluation and stabilization of therapy, please see product literature on Tensilon (edrophonium chloride).

⛔ Contraindications 42 words ▾

CONTRAINDICATIONS Pyridostigmine bromide tablets are contraindicated in mechanical intestinal or urinary obstruction, and particular caution should be used in its administration to patients with bronchial asthma. Care should be observed in the use of atropine for counteracting side effects, as discussed below.

⚠️ Warnings ~1 min read ▾

WARNINGS Although failure of patients to show clinical improvement may reflect underdosage, it can also be indicative of overdosage. As is true of all cholinergic drugs, overdosage of pyridostigmine bromide may result in cholinergic crisis, a state characterized by increasing muscle weakness which, through involvement of the muscles of respiration, may lead to death. Myasthenic crisis due to an increase in the severity of the disease is also accompanied by extreme muscle weakness, and thus may be difficult to distinguish from cholinergic crisis on a symptomatic basis.

Such differentiation is extremely important, since increases in doses of pyridostigmine bromide or other drugs of this class in the presence of cholinergic crisis or of a refractory or "insensitive" state could have grave consequences. Osserman and Genkins 1 indicate that the differential diagnosis of the two types of crisis may require the use of Tensilon TM (edrophonium chloride) as well as clinical judgment. The treatment of the two conditions obviously differs radically.

Whereas the presence of myasthenic crisis suggests the need for more intensive anticholinesterase therapy, the diagnosis of cholinergic crisis, according to Osserman and Genkins 1 calls for the prompt withdrawal of all drugs of this type. The immediate use of atropine in cholinergic crisis is also recommended. Atropine may also be used to abolish or obtund gastrointestinal side effects or other muscarinic reactions; but such use, by masking signs of overdosage, can lead to inadvertent induction of cholinergic crisis.

For detailed information on the management of patients with myasthenia gravis, the physician is referred to one of the excellent reviews such as those by Osserman and Genkins 2 , Grob 3 or Schwab 4,5 . Usage in Pregnancy The safety of pyridostigmine bromide during pregnancy or lactation in humans has not been established. Therefore, use of pyridostigmine bromide in women who may become pregnant requires weighing the drug's potential benefits against its possible hazards to mother and child.

🤒 Adverse Reactions 125 words ▾

ADVERSE REACTIONS The side effects of pyridostigmine bromide are most commonly related to overdosage and generally are of two varieties, muscarinic and nicotinic. Among those in the former group are nausea, vomiting, diarrhea, abdominal cramps, increased peristalsis, increased salivation, increased bronchial secretions, miosis and diaphoresis. Nicotinic side effects are comprised chiefly of muscle cramps, fasciculation and weakness.

Muscarinic side effects can usually be counteracted by atropine, but for reasons shown in the preceding section the expedient is not without danger. As with any compound containing the bromide radical, a skin rash may be seen in an occasional patient. Such reactions usually subside promptly upon discontinuance of the medication.

To report SUSPECTED ADVERSE REACTIONS, contact ANI Pharmaceuticals, Inc. at 1-855-204-1431 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

🤰 Pregnancy 43 words ▾

Usage in Pregnancy The safety of pyridostigmine bromide during pregnancy or lactation in humans has not been established. Therefore, use of pyridostigmine bromide in women who may become pregnant requires weighing the drug's potential benefits against its possible hazards to mother and child.

🧒 Pediatric Use 12 words ▾

Pediatric Use Safety and effectiveness in pediatric patients have not been established.

🧬 Clinical Pharmacology 57 words ▾

CLINICAL PHARMACOLOGY Pyridostigmine bromide inhibits the destruction of acetylcholine by cholinesterase and thereby permits freer transmission of nerve impulses across the neuromuscular junction. Pyridostigmine is an analog of neostigmine (Prostigmin TM ), but differs from it in certain clinically significant respects; for example, pyridostigmine is characterized by a longer duration of action and fewer gastrointestinal side effects.

📦 How Supplied / Storage and Handling 72 words ▾

HOW SUPPLIED Pyridostigmine Bromide Tablets USP, 60 mg are white, round, flat-faced, beveled edge tablets with a quadrisect functional score on one side and debossed with ‘ANI’ over ‘470’ on the other and are supplied in bottles of 100 (NDC 62559-470-01). Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Dispense in original container. Keep Pyridostigmine Bromide Tablets USP in a dry place with the silica gel enclosed.

📋 Description 54 words ▾

DESCRIPTION Pyridostigmine bromide is an orally active cholinesterase inhibitor. Chemically, pyridostigmine bromide is 3-hydroxy-1-methylpyridinium bromide dimethylcarbamate. Its structural formula is: Each Pyridostigmine Bromide Tablet USP intended for oral administration contains 60 mg of pyridostigmine bromide USP.

In addition, each tablet contains the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide and stearic acid. structure

⚠️ Precautions 48 words ▾

PRECAUTIONS Pyridostigmine is mainly excreted unchanged by the kidney 6,7,8 . Therefore, lower doses may be required in patients with renal disease, and treatment should be based on titration of drug dosage to effect 6,7 . Pediatric Use Safety and effectiveness in pediatric patients have not been established.

📚 References 190 words ▾

REFERENCES 1. Osserman KE, Genkins G. Studies in myasthenia gravis: Reduction in mortality rate after crisis.

JAMA . Jan 1963; 183:97-101. 2.

Osserman KE, Genkins G. Studies in myasthenia gravis. NY State J Med.

June 1961; 61:2076-2085. 3. Grob D.

Myasthenia gravis. A review of pathogenesis and treatment. Arch Intern Med.

Oct 1961; 108:615-638. 4. Schwab RS.

Management of myasthenia gravis. New Eng J Med. Mar 1963; 268:596-597.

5. Schwab RS. Management of myasthenia gravis.

New Eng J Med. Mar 1963; 268:717-719. 6.

Cronnelly R, Stanski DR, Miller RD, Sheiner LB. Pyridostigmine kinetics with and without renal function. Clin Pharmacol Ther.

1980; 28:No. 1, 78-81. 7.

Miller RD. Pharmacodynamics and pharmacokinetics of anticholinesterase. In: Ruegheimer E, Zindler M, ed.

Anaesthesiology. (Hamburg, Germany: Congress; Sep 14-21, 1980; 222-223.) (Int Congr. No.

538), Amsterdam, Netherlands: Excerpta Medica; 1981. 8. Breyer-Pfaff U, Maier U, Brinkmann AM, Schumm F.

Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis. Clin Pharmacol Ther. 1985;5:495-501.

All brand names listed are the trademarks of their respective owners and are not trademarks of ANI Pharmaceuticals, Inc. Distributed by: ANI Pharmaceuticals, Inc. Baudette, MN 56623 9894 Rev 03/25 ani-logo

📄 Package Label / Principal Display Panel 30 words ▾

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL Pyridostigmine Bromide Tablets USP, 60 mg NDC 62559- 470 -01 Unit-of-Use CAUTION: Extremely moisture sensitive. Do not remove desiccant. Close tightly. Rx only 100 Tablets 60mg_label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 62559-0470-01, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
3.4K
Units reimbursed last 4 qtrs
380.4K
Gross reimbursed last 4 qtrs
$126.4K
Avg / prescription
$36.69
Avg / unit
$0.3322
Latest quarter Q1 2026
841Rx
Medicaid pays / ea
$0.3322
gross reimbursed
vs
NADAC / ea
$0.2487
acquisition cost
=
Spread
+$0.0835
+34% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
37% FFS 63% MCO
Fee-for-service · 1,278 Rx Managed care · 2,166 Rx
State Medicaid map
Alaska: no data reported AK Maine: 15,165 units · 1,087 per 100k residents ME Washington: 11,604 units · 149 per 100k residents WA Idaho: no data reported ID Montana: 1,730 units · 153 per 100k residents MT North Dakota: no data reported ND Minnesota: 10,215 units · 178 per 100k residents MN Wisconsin: 8,413 units · 142 per 100k residents WI Michigan: 16,851 units · 168 per 100k residents MI New York: 62,085 units · 317 per 100k residents NY Vermont: no data reported VT New Hampshire: 3,972 units · 283 per 100k residents NH Oregon: 8,577 units · 203 per 100k residents OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 1,303 units · 40.6 per 100k residents IA Illinois: 6,189 units · 49.3 per 100k residents IL Indiana: 3,710 units · 54.1 per 100k residents IN Ohio: 17,011 units · 144 per 100k residents OH Pennsylvania: 35,900 units · 277 per 100k residents PA New Jersey: 8,840 units · 95.2 per 100k residents NJ Massachusetts: 8,114 units · 116 per 100k residents MA California: 33,107 units · 85.0 per 100k residents CA Utah: 7,954 units · 233 per 100k residents UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: 11,495 units · 186 per 100k residents MO Kentucky: 7,631 units · 169 per 100k residents KY West Virginia: no data reported WV Virginia: 11,246 units · 129 per 100k residents VA Maryland: 12,685 units · 205 per 100k residents MD Connecticut: 8,826 units · 244 per 100k residents CT Rhode Island: no data reported RI Arizona: 3,033 units · 40.8 per 100k residents AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: 2,402 units · 33.7 per 100k residents TN North Carolina: 13,218 units · 122 per 100k residents NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: 2,304 units · 50.4 per 100k residents LA Mississippi: 674 units · 22.9 per 100k residents MS Alabama: 1,740 units · 34.1 per 100k residents AL Georgia: 1,419 units · 12.9 per 100k residents GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 1,275 units · 4.2 per 100k residents TX Florida: 3,439 units · 15.2 per 100k residents FL
Units reimbursed · per 100k residents
4.21,087
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Maine 1,087 /100k
2 New York 317 /100k
3 New Hampshire 283 /100k
4 Pennsylvania 277 /100k
5 Connecticut 244 /100k
6 Utah 233 /100k
7 Maryland 205 /100k
8 Oregon 203 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Pyridostigmine Bromide — the program that covers self-administered drugs. 9 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Pyridostigmine Bromide. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$5.53M
Claims incl. refills
71.4K
Beneficiaries
45.1K
Spend / beneficiary
$122.42
Spend / claim
$77.39
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 62559-0461-90 · ANI 62559-0484-12 · ANI →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.